James M. Cleary, MD, PhD

Generation of a biliary tract cancer cell line atlas identifies molecular subtypes and therapeutic targets. Cancer Discov. 2025 May 12. View in: Pubmed

Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition. Science. 2025 May 08; 388(6747):eadk3487. View in: Pubmed

CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours. BJC Rep. 2025 Feb 27; 3(1):10. View in: Pubmed

Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer. N Engl J Med. 2025 Feb 06; 392(6):566-576. View in: Pubmed

A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer. Cancer Immunol Res. 2025 Jan 09; 13(1):9-22. View in: Pubmed

A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors. Clin Cancer Res. 2025 Jan 06; 31(1):35-44. View in: Pubmed

A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma. Ann Oncol. 2025 Apr; 36(4):426-443. View in: Pubmed

Chemical perturbations impacting histone acetylation govern colorectal cancer differentiation. bioRxiv. 2024 Dec 10. View in: Pubmed

Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature. 2024 Nov; 635(8040):E12. View in: Pubmed

Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. Clin Cancer Res. 2024 Nov 01; 30(21):4932-4942. View in: Pubmed

Toxicity Adaptive Lists Design: A Practical Design for Phase I Drug Combination Trials in Oncology. JCO Precis Oncol. 2024 Oct; 8:e2400275. View in: Pubmed

Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial. Clin Cancer Res. 2024 Oct 15; 30(20):4572-4583. View in: Pubmed

Blockade of IL1ß and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor. Cancer Immunol Res. 2024 Sep 03; 12(9):1221-1235. View in: Pubmed

Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma. Nat Commun. 2024 Aug 09; 15(1):6833. View in: Pubmed

Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity. Science. 2024 07 12; 385(6705):eadl6173. View in: Pubmed

Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and therapeutic targets. bioRxiv. 2024 Jul 08. View in: Pubmed

Immunological Checkpoint Blockade in Anal Squamous Cell Carcinoma: Dramatic Responses Tempered By Frequent Resistance. Curr Oncol Rep. 2024 Aug; 26(8):967-976. View in: Pubmed

Transcriptionally Active Human Papillomavirus Infection in a Minority of Esophageal Squamous Cell Carcinomas in North America. Am J Surg Pathol. 2024 Jul 01; 48(7):883-889. View in: Pubmed

Author Correction: Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting. NPJ Precis Oncol. 2024 May 06; 8(1):98. View in: Pubmed

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors. Clin Cancer Res. 2024 May 01; 30(9):1739-1749. View in: Pubmed

RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer. Clin Cancer Res. 2024 Apr 15; 30(8):1669-1684. View in: Pubmed

Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting. NPJ Precis Oncol. 2024 Apr 08; 8(1):87. View in: Pubmed

Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature. 2024 May; 629(8013):927-936. View in: Pubmed

FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma. J Hepatol. 2024 Aug; 81(2):265-277. View in: Pubmed

First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. J Clin Oncol. 2024 Jun 10; 42(17):2012-2020. View in: Pubmed

The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions. Future Oncol. 2024; 20(16):1057-1067. View in: Pubmed

Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders. J Immunother Cancer. 2024 01 25; 12(1). View in: Pubmed

Predicting response to immune checkpoint blockade therapy among mismatch repair-deficient patients using mutational signatures. medRxiv. 2024 Jan 21. View in: Pubmed

NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma. Br J Cancer. 2024 02; 130(3):476-482. View in: Pubmed

Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (COSMIC-021). EClinicalMedicine. 2024 Jan; 67:102376. View in: Pubmed

A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Clin Cancer Res. 2023 12 15; 29(24):5047-5056. View in: Pubmed

Retraction Note: Polymerase ? inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer. Nat Commun. 2023 Dec 11; 14(1):8193. View in: Pubmed

Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer. Clin Cancer Res. 2023 11 14; 29(22):4627-4643. View in: Pubmed

Replicative stress in gastroesophageal cancer is associated with chromosomal instability and sensitivity to DNA damage response inhibitors. iScience. 2023 Nov 17; 26(11):108169. View in: Pubmed

Diffuse Cutaneous Aphthosis After Combined Targeted Cancer Therapies and Responsive to Pentoxifylline. JAMA Dermatol. 2023 10 01; 159(10):1136-1139. View in: Pubmed

G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans. J Immunother Cancer. 2023 06; 11(6). View in: Pubmed

Highly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases in Patients With GI Cancer. JCO Precis Oncol. 2023 06; 7:e2200572. View in: Pubmed

Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. Oncologist. 2023 05 08; 28(5):425-432. View in: Pubmed

Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors. Cancer. 2023 06 15; 129(12):1904-1918. View in: Pubmed

SMARCA4 Mutations in Carcinomas of the Esophagus, Esophagogastric Junction, and Stomach. Mod Pathol. 2023 06; 36(6):100183. View in: Pubmed

USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. Cell Rep Med. 2023 04 18; 4(4):101007. View in: Pubmed

Correction to: A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C. Cancer Chemother Pharmacol. 2023 Apr; 91(4):301. View in: Pubmed

Replicative stress in gastroesophageal adenocarcinoma is associated with chromosomal instability and sensitivity to DNA damage response inhibitors. bioRxiv. 2023 Mar 28. View in: Pubmed

A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus. Future Oncol. 2023 Apr; 19(11):739-752. View in: Pubmed

Polymerase ? inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer. Nat Commun. 2023 03 13; 14(1):1390. View in: Pubmed

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. Nat Commun. 2023 02 06; 14(1):630. View in: Pubmed

A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C. Cancer Chemother Pharmacol. 2023 04; 91(4):291-300. View in: Pubmed

Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Cancer Res. 2023 02 03; 83(3):441-455. View in: Pubmed

Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial. JAMA Netw Open. 2023 01 03; 6(1):e2249720. View in: Pubmed

Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer. JCO Precis Oncol. 2023 01; 7:e2200342. View in: Pubmed

How we treat advanced biliary tract cancers in the second-line setting. Clin Adv Hematol Oncol. 2023 01; 21(1):35-42. View in: Pubmed

Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma. Cancers (Basel). 2022 Dec 16; 14(24). View in: Pubmed

Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Clin Cancer Res. 2022 12 01; 28(23):5167-5179. View in: Pubmed

Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma. NPJ Precis Oncol. 2022 Sep 02; 6(1):61. View in: Pubmed

Physical activity in older adults with metastatic gastrointestinal cancer: a pilot and feasibility study. BMJ Open Sport Exerc Med. 2022; 8(2):e001353. View in: Pubmed

ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series. JCO Precis Oncol. 2022 04; 6:e2200015. View in: Pubmed

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022 03; 603(7903):942-948. View in: Pubmed

Risk of Cancer in Inflammatory Bowel Disease and Pitfalls in Oncologic Therapy. J Gastrointest Cancer. 2023 Jun; 54(2):357-367. View in: Pubmed

Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. JNCI Cancer Spectr. 2022 03 02; 6(2). View in: Pubmed

Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell. 2021 12 09; 184(25):6119-6137.e26. View in: Pubmed

Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report. J Gastrointest Oncol. 2021 Dec; 12(6):3133-3140. View in: Pubmed

Early TP53 Alterations Shape Gastric and Esophageal Cancer Development. Cancers (Basel). 2021 Nov 24; 13(23). View in: Pubmed

A woman presenting with an unusual cause of fulminant liver failure and sepsis. Clin Res Hepatol Gastroenterol. 2022 03; 46(3):101836. View in: Pubmed

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol. 2021 Nov 01; 7(11):1669-1677. View in: Pubmed

Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival. J Immunother Cancer. 2021 09; 9(9). View in: Pubmed

Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2021 Sep 01; 27(17):4940. View in: Pubmed

A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. NPJ Precis Oncol. 2021 Aug 05; 5(1):74. View in: Pubmed

Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma. Clin Cancer Res. 2021 12 15; 27(24):6622-6637. View in: Pubmed

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021 07 03; 398(10294):27-40. View in: Pubmed

Revisiting patient-related barriers to cancer pain management in the context of the US opioid crisis. Pain. 2021 06 01; 162(6):1840-1847. View in: Pubmed

Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. Pancreatology. 2021 May 15. View in: Pubmed

FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discov. 2021 10; 11(10):2488-2505. View in: Pubmed

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021 04 01; 384(13):1191-1203. View in: Pubmed

Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. Oncologist. 2021 07; 26(7):610-618. View in: Pubmed

Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors. Clin Cancer Res. 2021 06 01; 27(11):2996-3004. View in: Pubmed

A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2021 05 01; 27(9):2470-2480. View in: Pubmed

The World Cancer Declaration: time to consolidate wins and work towards 2025. Lancet Oncol. 2021 03; 22(3):296-298. View in: Pubmed

Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. Clin Cancer Res. 2021 03 15; 27(6):1695-1705. View in: Pubmed

Fibroblast Growth Factor Receptor Inhibitors and Nonuremic Calciphylaxis. JAMA Dermatol. 2021 01 01; 157(1):119-121. View in: Pubmed

Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial. Cancers (Basel). 2020 Nov 20; 12(11). View in: Pubmed

Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors. J Immunother Cancer. 2020 10; 8(2). View in: Pubmed

High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors. Sci Signal. 2020 06 16; 13(636). View in: Pubmed

Biomarker-Guided Development of DNA Repair Inhibitors. Mol Cell. 2020 06 18; 78(6):1070-1085. View in: Pubmed

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 06; 21(6):796-807. View in: Pubmed

A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR. Invest New Drugs. 2020 10; 38(5):1483-1494. View in: Pubmed

Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) - An ACCRU Network study. Ann Oncol. 2018 Jun; 29 Suppl 5:v105. View in: Pubmed

Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. Ann Oncol. 2020 01; 31(1):88-95. View in: Pubmed

Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket' trial. Ann Oncol. 2019 Jul; 30 Suppl 4:iv127. View in: Pubmed

Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: preliminary results. Ann Oncol. 2019 Jul; 30 Suppl 4:iv122-iv123. View in: Pubmed

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol Hepatol. 2019 09; 4(9):711-720. View in: Pubmed

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol. 2019 08; 20(8):1070-1082. View in: Pubmed

Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors. Invest New Drugs. 2020 04; 38(2):419-432. View in: Pubmed

Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial. JAMA. 2019 04 09; 321(14):1370-1379. View in: Pubmed

FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. Cancer. 2019 07 01; 125(13):2213-2221. View in: Pubmed

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations. Clin Cancer Res. 2019 05 01; 25(9):2699-2707. View in: Pubmed

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018 09; 8(9):1096-1111. View in: Pubmed

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018 02; 8(2):196-215. View in: Pubmed

Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies. Br J Cancer. 2017 Oct 24; 117(9):1258-1268. View in: Pubmed

Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017 07 27; 547(7664):453-457. View in: Pubmed

Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC). Ann Oncol. 2017 Jun; 28 Suppl 3:iii151. View in: Pubmed

LBA-004Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC). Ann Oncol. 2017 Jun 01; 28(suppl_3). View in: Pubmed

A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer. 2017 06 01; 123(11):1979-1988. View in: Pubmed

A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone. Invest New Drugs. 2017 04; 35(2):189-197. View in: Pubmed

Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors. Clin Cancer Res. 2017 Jul 15; 23(14):3520-3528. View in: Pubmed

Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016 11 17; 1(19):e87062. View in: Pubmed

A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan. Invest New Drugs. 2017 02; 35(1):68-78. View in: Pubmed

Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma. Clin Cancer Res. 2017 Jun 15; 23(12):3214-3222. View in: Pubmed

Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer. BMC Cancer. 2016 07 13; 16:468. View in: Pubmed

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 07 01; 22(13):3227-37. View in: Pubmed

Costs, affordability, and feasibility of an essential package of cancer control interventions in low-income and middle-income countries: key messages from Disease Control Priorities, 3rd edition. Lancet. 2016 May 21; 387(10033):2133-2144. View in: Pubmed

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 Feb 15; 22(4):847-57. View in: Pubmed

A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2015 10; 33(5):1100-7. View in: Pubmed

Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015 May 14; 372(20):1909-19. View in: Pubmed

A phase 1 study of ABT-806 in subjects with advanced solid tumors. Invest New Drugs. 2015 Jun; 33(3):671-8. View in: Pubmed

Update on the role of imaging in management of metastatic colorectal cancer. Radiographics. 2014 Nov-Dec; 34(7):1908-28. View in: Pubmed

A Phase I, dose-finding study in patients with advanced solid malignancies of the oral ?-secretase inhibitor PF-03084014. Clin Cancer Res. 2015 Jan 01; 21(1):60-7. View in: Pubmed

A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. Invest New Drugs. 2014 Oct; 32(5):937-45. View in: Pubmed

Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2014 Jun; 19(6):637-8. View in: Pubmed

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014 May; 4(5):546-53. View in: Pubmed

Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma. J Natl Compr Canc Netw. 2014 Mar 01; 12(3):323-6; quiz 326. View in: Pubmed

Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol. 2014 Jan 10; 32(2):68-75. View in: Pubmed

Decade of molecular targeted therapy: abdominal manifestations of drug toxicities--what radiologists should know. AJR Am J Roentgenol. 2012 Jul; 199(1):58-64. View in: Pubmed

Imaging features of bowel toxicities in the setting of molecular targeted therapies in cancer patients. Br J Radiol. 2012 Oct; 85(1018):1420-6. View in: Pubmed

A phase I dose-escalation study of the novel gamma secretase inhibitor PF-03084014 in patients (pts) with advanced solid tumors. J Clin Oncol. 2011 May 20; 29(15_suppl):3100. View in: Pubmed

Two-dimensional phase I study of neratinib (NER) combined with temsirolimus (TEM) in patients (Pts) with solid tumors. J Clin Oncol. 2011 May 20; 29(15_suppl):3027. View in: Pubmed

A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results. J Clin Oncol. 2011 May 20; 29(15_suppl):3080. View in: Pubmed

Combination study of navitoclax with gemcitabine (G) in patients (pts) with solid tumors. J Clin Oncol. 2011 May 20; 29(15_suppl):3067. View in: Pubmed

MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with advanced solid tumors: Phase I study of multiple treatment schedules. J Clin Oncol. 2011 May 20; 29(15_suppl):3013. View in: Pubmed

Impact of RECIST 1.1 modifications on clinical trial eligibility. J Clin Oncol. 2011 May 20; 29(15_suppl):e16555. View in: Pubmed

A phase I study of the novel DNA topoisomerase-1 inhibitor, TLC388, administered intravenously to patients with advanced solid tumors. J Clin Oncol. 2011 May 20; 29(15_suppl):e13618. View in: Pubmed

Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors. J Clin Oncol. 2011 May 20; 29(15_suppl):3033. View in: Pubmed

Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors. J Clin Oncol. 2011 May 20; 29(15_suppl):3005. View in: Pubmed

Phase I study of PF-04554878, a second-generation focal adhesion kinase (FAK) inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2011 May 20; 29(15_suppl):3002. View in: Pubmed

A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: Updated report. J Clin Oncol. 2011 May 20; 29(15_suppl):3051. View in: Pubmed

Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer. 2010 Dec 01; 116(23):5400-6. View in: Pubmed

Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib. J Clin Oncol. 2010 Aug 10; 28(23):e390-2. View in: Pubmed

Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer. Curr Oncol Rep. 2010 Mar; 12(2):87-94. View in: Pubmed

Validation of a fully autonomous phosphate analyser based on a microfluidic lab-on-a-chip. Water Sci Technol. 2010; 61(7):1811-8. View in: Pubmed

Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. Oncologist. 2009 Nov; 14(11):1095-105. View in: Pubmed

Integrating a narrative medicine telephone interview with online life review education for cancer patients: lessons learned and future directions. J Soc Integr Oncol. 2009; 7(1):19-25. View in: Pubmed

Effects of prayer and religious expression within computer support groups on women with breast cancer. Psychooncology. 2007 Jul; 16(7):676-87. View in: Pubmed

Parenteral antioxidant treatment preserves temporal discrimination following intrahippocampal aggregated Abeta(1-42) injections. Behav Pharmacol. 2005 Jul; 16(4):237-42. View in: Pubmed

Prolactin modulates the naive B cell repertoire. J Clin Invest. 2003 Jan; 111(2):275-83. View in: Pubmed

Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Abeta(1-42) injections in the rat. Brain Res. 2002 Nov 01; 954(1):1-10. View in: Pubmed

Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest. 2002 Jun; 109(12):1625-33. View in: Pubmed

RGS18 is a myeloerythroid lineage-specific regulator of G-protein-signalling molecule highly expressed in megakaryocytes. Biochem J. 2001 Oct 01; 359(Pt 1):109-18. View in: Pubmed

Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 1998 Apr 15; 90(8):611-6. View in: Pubmed

Anticipation in schizophrenia: biology or bias? Am J Med Genet. 1997 May 31; 74(3):275-80. View in: Pubmed

Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor. J Clin Oncol. 1997 Feb; 15(2):781-9. View in: Pubmed

Glucose metabolism in 'Sphingomonas elodea': pathway engineering via construction of a glucose-6-phosphate dehydrogenase insertion mutant. Microbiology (Reading). 1995 Sep; 141 ( Pt 9):2339-50. View in: Pubmed

Clean intermittent catheterization: safe, cost-effective bladder management for male residents of VA nursing homes. J Am Geriatr Soc. 1995 Aug; 43(8):865-70. View in: Pubmed

Mitochondrial DNA mutations in an outbreak of optic neuropathy in Cuba. Neurology. 1994 May; 44(5):843-5. View in: Pubmed

Identification, genetic and biochemical analysis of genes involved in synthesis of sugar nucleotide precursors of xanthan gum. J Gen Microbiol. 1993 Mar; 139(3):447-57. View in: Pubmed

Location and cloning of the ketal pyruvate transferase gene of Xanthomonas campestris. J Bacteriol. 1991 Dec; 173(23):7519-24. View in: Pubmed

Chromosomal replication origin from the marine bacterium Vibrio harveyi functions in Escherichia coli: oriC consensus sequence. Proc Natl Acad Sci U S A. 1983 Mar; 80(5):1164-8. View in: Pubmed

Chromosomal replication origins (oriC) of Enterobacter aerogenes and Klebsiella pneumoniae are functional in Escherichia coli. J Bacteriol. 1982 Dec; 152(3):983-93. View in: Pubmed

Primary structure of the chromosomal origins (oriC) of Enterobacter aerogenes and Klebsiella pneumoniae: comparisons and evolutionary relationships. J Bacteriol. 1982 Jun; 150(3):1467-71. View in: Pubmed